

CERTIFICATE

2025

Molekularpathologie-BW GbR
Schloßstraße 56
70176 Stuttgart
Germany

has participated in the proficiency test

ESP/QuIP Lung Cancer Related Markers – Mutations: *EGFR*, *KRAS*, *BRAF* (MolPath)

(Trial date 20.10.2025 – 03.11.2025)

by using Next Generation Sequencing (NGS),
Thermo Fisher Scientific: Oncomine™ Dx Express Test,
Thermo Fisher Scientific: IonTorrent Genexus™

and completed the following sections

EGFR – **with success**

KRAS – **with success**

BRAF – **with success**

Berlin, January 28, 2026



Prof. Dr. med. Claudia Wickenhauser
Quality in Pathology - QuIP GmbH



Thomas Pilz, Managing Director
Quality in Pathology - QuIP GmbH

Lead panel institute of the proficiency test:

Prof. Dr. rer. nat. S. Merkelbach-Bruse, Dr. rer. nat. J. Fassunke, Department of Pathology, University Hospital Cologne, Germany;
Prof. MUDr. A. Ryška, Department of Pathology, Charles University Medical Faculty, Hradec Kralove, Czech Republic

This certificate includes the separate individual evaluation of the test and the corresponding proficiency test report. This certificate is only valid in combination with the amendment on the next page.

This proficiency test was organized by:

Qualitätssicherungs-Initiative Pathologie QuIP GmbH /
Reinhardtstr. 1 / 10117 Berlin / office@quip.eu / www.qualityinpathology.com

Amendment to the
CERTIFICATE 2025
for the participation in the proficiency test
ESP/QuIP Lung Cancer Related Markers - Mutations: *EGFR*, *KRAS*,
BRAF (MolPath)

This certificate confirms only the successful testing of mutations that are detectable with the method specified on the first page. The method used has no known limitations for the detection of clinically relevant *EGFR* mutations.